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 8 
Abstract 9 
 This study reports the effect of surfactant charge and concentration on the permeation 10 
of four model compounds (benzocaine, benzotriazole, ibuprofen and lidocaine). Surfactant 11 
charge was systematically varied using a range of surfactants that are known to possess 12 
specific head group charges, namely an anionic, a cationic, a zwitterionic and a neutral form 13 
over a series of surfactant concentrations, i.e. where possible, both above, and below, the 14 
critical micellar concentration for each surfactant. It was found that there was almost always 15 
a systematic reduction in permeation as the concentration of surfactant increased despite the 16 
wide range of physicochemical properties exhibited by the four model compounds studied. 17 
Overall, it was concluded that the presence of surfactant does generally seem to reduce 18 
permeation, regardless of the compound in question, and that the effect is surfactant 19 
concentration, as well as charge, dependent.  20 
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Introduction 30 
 Skin is a natural barrier yet despite this, is often the focus of permeation analysis in 31 
both the cosmetic and pharmaceutical industry as the rate, and extent, of transdermal 32 
permeation must be quantified irrespective of whether or not it is desired. Factors affecting 33 
permeation are complex including the properties of the skin (such as age, location, 34 
condition)[1] along with the physicochemical properties of the formulation (such as 35 
lipophilicity, presence of excipients and molecular size)[2]. Transdermal permeation studies 36 
are frequently undertaken using excised human or animal skin although in recent years this 37 
has become unfavourable for several reasons, the former mainly for economic reasons and 38 
the latter mainly for ethical reasons. Both types of excised skin exhibit notoriously low levels 39 
of reproducibility and with recent changes in legislation regarding cosmetic analytical testing, 40 
have encouraged the development of synthetic skin mimics [3, 4]. These skin mimic systems 41 
offer a host of advantages including greater reproducibility, often reduced cost[5] and 42 
elimination of the need for ethical approval. One such skin mimic that has become popular 43 
for investigating transdermal permeation is a polymer known as polydimethylsiloxane, also 44 
known as PDMS or simply as silicone membrane. PDMS is a commonly used polymer that 45 
has a wide range of industrial applications, for example, gas and liquid separation[6], 46 
pervaporation[7, 8] and microfluidic devices[9]. More importantly, PDMS membrane has 47 
been reported to produce good correlation with an in vivo situation in a case whereby the 48 
penetrant lipophilicity was the prime determinant of compound permeation[10]. However, as 49 
PDMS is a very simplified model of skin it has the advantage of significantly increasing the 50 
level of reproducibility in data acquired yet has the disadvantage of potentially behaving 51 
differently to skin under certain conditions. Several factors have already been found to effect 52 
permeation including ionisation (as a result of pH)[11], membrane thickness[12] and solvent 53 
selection (i.e. donor and receptor solution composition)[13]. 54 
 Formulations can be tailored to permeate skin at a rate suited to their requirements, 55 
for example, they can be encouraged to permeate by the addition of permeation enhancers[14, 56 
15] or discouraged by the addition of permeation retardants[16]. Interestingly it has been 57 
found that a particular compound may act as an enhancer in one formulation yet a retardant in 58 
another, further complicating the situation. However, what is not currently fully understood is 59 
whether or not skin mimics, such as PDMS, behave in a similar manner to that seen in vivo 60 
and if there is a pattern in their ability to enhance or retard permeation. Previous research 61 
from within our group has investigated the effect of temperature on permeation using PDMS 62 
and to a very limited extent, the effect of the presence of two surfactants, namely sodium 63 
dodecyl sulfate and Brij 35, on two structurally similar paraben-based compounds[17]. In this 64 
study it was found that the effect on permeation for these two compounds differed for the two 65 
surfactants implying there was a surfactant-specific effect although general conclusions could 66 
not be made from such a limited study. 67 
 Surfactants can be divided into four categories, depending upon the overall charge 68 
located on the head group of the amphiphilic molecule: anionic, cationic, zwitterionic or non-69 
ionic. Upon reaching a surfactant-specific concentration (the critical micellar concentration, 70 
i.e. CMC) molecules will spontaneously aggregate to form micellar structures which then 71 
display dissimilar properties to the unaggregated molecules. Surfactants are renowned for 72 
their ability to modify transdermal permeation[18] yet their behaviour, with respect to PDMS, 73 
is not well understood regarding surfactant choice or concentration. 74 
 In this paper, a systematic study into the effects of the presence of all four categories 75 
of surfactant over a wide range of concentrations with a selection of chemically-diverse 76 
model compounds seeks to create a better understanding of the interactions exhibited between 77 
permeation and the addition of such molecules.  78 
 79 
Materials and Methods 80 
Materials 81 
 Polydimethylsiloxane membrane (PDMS) was used as purchased (ATOS Medical, 82 
Sweden) with a standard thickness of 130 µm and cut to size as required.  83 
Compound Purity Supplier 
Benzocaine > 99.0 % Sigma-Aldrich 
Benzotriazole 99.0 % Sigma-Aldrich 
Brij 35 Proteomics grade BDH Lab. 
CHAPS > 98.0 % Fisher Scientific 
CTAB > 98.0 %  Sigma-Aldrich 
Dipotassium hydrogen 
phosphate 
> 98 % Fisher Scientific 
Ibuprofen > 97.0 % BASF 
Lidocaine > 98.0 %  Sigma-Aldrich 
Mono potassium 
dihydrogen phosphate 
> 99.0 % Fisher Scientific 
SDS > 99.0 % Sigma-Aldrich 
Tween 80 Super refined grade Croda International 
 84 
Methods 85 
Permeation studies 86 
PDMS membrane was soaked in phosphate buffer solution (0.02 M pH 7.4 and 0.15 87 
M NaCl) for 30 minutes prior to being mounted in the flow-through diffusion cells 88 
(PermeGear Inc. USA). After assembly the cells were placed on a cell warmer, maintained at  89 
a temperature of 32 °C. To start each permeation experiment, 0.8 mL of the donor solution 90 
containing model compound and/or surfactant was added to the cell. In all experiments the 91 
concentration of the model compounds in the donor solution was 1 mg/mL with surfactant 92 
present at concentrations of 0, 4, 8 or 20 mM for SDS, Brij 35, Tween 80, CTAB and 0, 2, 4 93 
or 20 mM for CHAPS. Phosphate buffer saline was pumped through the cells at 5 mL/h. The 94 
samples were collected by means of a fraction collector at the predetermined time intervals 95 
(0.75, 1.5, 2.25, 3, 3.75, 4.5, 5.25 and 6 h). Quantification was undertaken using UV 96 
spectroscopy (benzoicaine at 258 nm, benzotriazole at 262 nm, ibuprofen at 225 nm and 97 
lidocaine at 219 nm). All experiments were conducted in triplicate with the mean value 98 
shown with standard deviation based error limits. All flow-through cells used in this study 99 
had a diffusion area of 0.554 cm2. The steady state flux (𝐽) was determined (noting the 100 
importance of maintaining sink conditions[19]) from the slope of the best-fit linear plot of the 101 
cumulative amount of the drug permeated per unit area versus time where flux is expressed 102 
as: 103 
𝐽 =
𝐶0𝐾𝐷
𝐿
= 𝐶0𝐾𝑃     104 
where 𝐾𝑃 is the permeability coefficient, C0 is the drug concentration, K is the partition 105 
coefficient, D is the diffusion coefficient and L is the thickness of the membrane[20]. All 106 
values are expressed as the mean values of three replicates shown with standard deviation 107 
based error limits. Statistical analysis was carried out using Minitab software (V.16).  108 
Characterisation of surfactant-membrane interactions 109 
Two analytical techniques were used to further characterise the surfactant-membrane 110 
interactions in an attempt to determine if the interaction only occurs in situ or, is a more 111 
permanent modification to the surface. Firstly, differential scanning calorimetry (DSC) was 112 
undertaken whereby PDMS membrane was cut to an appropriate size for investigation and 113 
left overnight in phosphate buffer (pH 7.4) with, or without, the individual surfactants present 114 
at a concentration of 20 mM. The samples were then dried with soft tissue to remove excess 115 
liquid. DSC scans of the untreated and the treated samples were performed using a DSC 1 116 
(Mettler-Toledo Ltd., Leicester, UK), at a heating rate of 1 °C/min over a range of -60 °C to -117 
20 °C. All DSC thermograms were assessed with regard to the phase transition of PDMS 118 
membrane, which was reported to be -40 °C [27].          119 
 FT-IR analysis of the untreated and treated membranes (as described above) was 120 
performed using a Nicolet IR 380 spectrometer. The samples were cut into suitable sizes and 121 
placed in direct contact with the diamond crystal of the spectrometer over the range of 4000-122 
400 cm-1 and analysed with Omnic software (version 7.2a). 123 
 124 
Results and Discussion 125 
Four model compounds were analysed to investigate the permeation effect of 126 
surfactant charge across PDMS membrane. The model compounds were benzocaine, 127 
benzotriazole, ibuprofen and lidocaine, having a diverse range of lipophilicities ranging from 128 
a log P of 1.2 for benzotriazole[21] to 3.6 for ibuprofen[11]. The surfactants were chosen to 129 
include all four categories, namely SDS (anionic), CTAB (cationic), CHAPS (zwitterionic) 130 
and Brij 35 (non-ionic). 131 
As a control, the permeation of the model compounds through silicone membrane 132 
were assessed at 32 °C with no surfactant present in the donor solution over a period of 6 133 
hours. Three additional solutions were then prepared containing the surfactants at three 134 
different concentrations (4, 8 and 20 mM for SDS, CTAB, Brij 35 and Tween 80, and 2, 4 135 
and 20 mM for CHAPS), and the permeation of the model compounds was measured. The 136 
concentrations of the surfactants were chosen to be either below, equal or above the critical 137 
micellar concentration (CMC). Two permeation parameters, namely, steady-state flux (𝐽) and 138 
the cumulative amount of compound permeated after 6 hours (Q6), were calculated from the 139 
data obtained using a flow-through diffusion cell system and are summarised in Tables 1 and 140 
2. The steady-state flux (𝐽) values of the compounds were analysed statistically using One-141 
way ANOVA to determine p-values to confirm whether the variability in surfactant type 142 
and/or concentration caused a significant difference in compound permeability.  143 
 In a simple scenario, all donor solutions of the same penetrant should yield an 144 
identical steady-state flux across a membrane, not depending on the composition of the 145 
vehicle, provided that the formulation components do not interact with the membrane [22]. 146 
Therefore, the steady-state flux of a compound from donor solutions from any of the 147 
surfactant-containing vehicles would be anticipated to be same. However, the data presented 148 
in Table 1 demonstrate that the flux values of the penetrants are not identical. In all cases, 149 
interactions between either surfactant and membrane, or drug and surfactant were observed 150 
that could possibly have altered the compound flux across the membrane, i.e. these 151 
interactions were affected by surfactant concentration and surfactant type.  152 
 153 
 154 
Table 1 155 
Steady-state flux values of four model compounds in the presence of SDS, CTAB, CHAPS 156 
and Brij 35 across silicone membrane 157 
Surfactant in the 
donor phase 
Steady-state flux (µg/cm2/h) of compound 
Benzocaine Benzotriazole Ibuprofen Lidocaine 
SDS 0 mM 97.92 ± 2.22 18.33 ± 0.80 26.25 ± 1.95 69.70 ± 1.12 
SDS 4 mM 89.80 ± 1.70 17.94 ± 0.43 27.53 ± 1.40 43.07 ± 1.70 
SDS 8 mM 89.16 ± 0.85 13.75 ± 0.23 23.37 ± 1.27 31.69 ± 3.10 
SDS 20 mM 62.87 ± 1.84 12.21 ± 0.26 21.29 ± 1.55 13.54 ± 1.08 
     
CTAB 0 mM 104.59 ± 3.22 9.96 ± 0.58 21.15 ± 1.46 56.98 ± 6.64 
CTAB 4 mM 70.77 ± 6.79 9.51 ± 0.27 9.82 ± 0.55 52.93 ± 4.63 
CTAB 8 mM 56.71 ± 2.94 8.00 ± 0.25 5.12 ± 0.75 47.77 ± 6.77 
CTAB 20 mM 38.82 ± 5.48 6.88 ± 0.23 2.37 ± 0.31 37.66 ± 3.23 
     
CHAPS 0 mM 107.95 ± 3.99 10.46 ± 0.53 32.13 ± 1.12 55.28 ± 6.64 
CHAPS 2 mM 105.10 ± 6.75 10.14 ± 0.51 32.48 ± 1.76 54.68 ± 3.73 
CHAPS 4 mM 106.75 ± 5.42 9.45 ± 0.26 18.50 ± 0.39 52.62 ± 3.05 
CHAPS 20 mM 87.53 ± 4.10 9.47 ± 0.18 9.90 ± 1.93 49.94 ± 4.01 
     
Brij 35 0 mM 102.07 ± 6.88 13.30 ± 0.09 31.00 ± 1.83 64.84 ± 3.66 
Brij 35 4 mM 77.54 ± 5.67 13.04 ± 0.73 26.50 ± 1.69 66.96 ± 3.09 
Brij 35 8 mM 63.29 ± 2.61 10.62 ± 0.43 17.49 ± 0.12 60.48 ± 4.07 
Brij 35 20 mM 43.36 ± 1.15 9.58 ± 0.37 12.29 ± 0.33 57.44 ± 2.57 
 158 
 To understand the effect of individual surfactant type and concentration, the 159 
cumulative amount of compound permeated after 6 h was also considered (Table 2). It can be 160 
seen from Table 2 that the amount of the model compounds permeated after 6 hours varies 161 
with a change in surfactant concentration and type. Moreover, the compounds’ permeability 162 
profiles were shown as percentage permeated after 6 h, graphically, in Figs. 1 – 4 in an 163 
attempt to provide a comprehensive understanding of the relationship between the surfactant 164 
concentration and the reduction in the amount permeated. In all of the figures (Figs. 1 – 4) the 165 
amount permeated after 6 h for the control solution was normalised to 100 %, with values for 166 
other solutions calculated accordingly. Such presentations offer a convenient way of 167 
comparing different active compounds in terms of the effect on their permeation by a 168 
surfactant.      169 
 170 
Table 2  171 
Cumulative amount permeated after 6 hours (Q6) of four model compounds in the presence of 172 
various surfactants across PDMS membrane  173 
Surfactant in the 
donor phase 
 Amount of compound permeated (µg/cm2) after 6 h  
Benzocaine Benzotriazole Ibuprofen Lidocaine 
SDS 0 mM 570.65 ± 
13.00 
110.80 ± 3.90 155.67 ± 10.95 410.35 ± 8.29 
SDS 4 mM 526.98 ± 
11.19 
108.55 ± 2.60 163.60 ± 8.24 253.74 ± 11.36 
SDS 8 mM 520.29 ± 4.56 83.72 ± 1.33 138.18 ± 6.53 187.76 ± 17.99 
SDS 20 mM 370.01 ± 
10.93 
74.63 ± 1.24 126.20 ± 9.45 81.17 ± 6.68 
     
CTAB 0 mM 611.95 ± 
20.24 
60.06 ± 3.23 126.09 ± 8.67 333.97 ± 37.25 
CTAB 4 mM 412.35 ± 
37.75 
57.66 ± 2.03 60.67 ± 3.51 314.68 ± 27.91 
CTAB 8 mM 336.94 ± 
17.46 
48.92 ± 1.40 31.88 ± 4.27 283.63 ± 41.67 
CTAB 20 mM 229.99 ± 
31.91 
41.99 ± 1.41 15.23 ± 1.80 221.73 ± 20.32 
     
CHAPS 0 mM 635.17 ± 
23.38 
62.59 ± 3.57 188.30 ± 7.40 322.81 ± 39.99 
CHAPS 2 mM 617.92 ± 61.18 ± 3.07 194.57 ± 10.60 318.98 ± 21.29 
41.17 
CHAPS 4 mM 630.04 ± 
31.97 
56.85 ± 1.67 109.94 ± 1.93 308.78 ± 19.19 
CHAPS 20 mM 517.98 ± 
24.85 
56.72 ± 1.16 59.05 ± 11.19 293.14 ± 24.37 
     
Brij 35 0 mM 600.99 ± 
39.63 
80.90 ± 0.64 185.47 ± 10.62 380.52 ± 22.63 
Brij 35 4 mM 456.40 ± 
32.33 
79.45 ± 4.24 158.84 ± 10.30 394.04 ± 18.87 
Brij 35 8 mM 372.96 ± 
14.80 
64.79 ± 2.29 105.09 ± 0.51 354.49 ± 24.16 
Brij 35 20 mM 257.46 ± 6.52 58.10 ± 2.22 74.88 ± 2.15 337.36 ± 15.73 
  In the first set of experiments, permeation of benzocaine, benzotriazole, ibuprofen and 174 
lidocaine through silicone membrane from the donor solutions containing SDS (an anionic 175 
surfactant) at three different concentrations (4, 8 & 20 mM) were evaluated. It can be seen in 176 
Fig. 1 that the presence of the anionic surfactant significantly (p < 0.05) affected the transport 177 
of all compounds over a period of 6 h with the lowest percentage permeated observed at the 178 
highest concentration of surfactant examined.  179 
Overall, the results here would indicate that the reduction in the amount permeated is 180 
directly related to the concentration of surfactant. These results are similar to the findings of a 181 
recent study where Waters and co-researchers reported a decrease in the permeation of 182 
paraben derivatives with an increase in SDS concentration in the donor solution [17].  It can 183 
be seen in Fig. 1 that the maximum reduction in permeation of each compound resulted from 184 
20 mM SDS being present in the donor compartment, with lidocaine experiencing a reduction 185 
of 80.22 %, being the greatest reduction when compared with other model compounds, and 186 
ibuprofen having the least reduction of 18.93 %.   187 
 188 
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 197 
 198 
Fig. 1. Effect of the presence of SDS on compound permeation across PDMS membrane.  199 
0.00
20.00
40.00
60.00
80.00
100.00
120.00
0 4 8 12 16 20 24
%
 p
er
m
ea
te
d
 a
ft
er
 6
 h
SDS concentration (mM)
Benzocaine Benzotriazole
Ibuprofen Lidocaine
   200 
The other noticeable phenomenon in Fig. 1 is that the permeability profiles of 201 
benzocaine, benzotriazole, and ibuprofen, position themselves, more likely, to be part of a 202 
group whereas lidocaine is very distinctive in this regard. From a physicochemical 203 
perspective, lidocaine is basic in nature whereas the other three compounds are regarded as 204 
acidic. Thus, upon ionisation in buffer solution, lidocaine produces cations while benzocaine, 205 
benzotriazole, and ibuprofen, produce anions. Hence, the compounds, in donor solutions, 206 
would exist as ionised (charged) species and unionised (neutral) species. As PDMS 207 
membrane is predominantly hydrophobic in nature, only the neutral species can pass through 208 
the membrane while the charged species stay in the donor solution. Although both the neutral 209 
and charged (anionic and cationic) species can interact with SDS, the interaction of SDS with 210 
an anion could not be the same as that with a cation, and this variation might result in the 211 
compounds experiencing dissimilar effects in the presence of SDS.         212 
It is clear that the influence on compound permeability can result from a 213 
multidimensional interaction or a mixture of interactions, such as, surfactant-membrane, 214 
and/or surfactant-drug interactions. One previous study from our group suggested surfactant-215 
membrane interaction to be a triggering factor in the reduction of compound permeation[17]. 216 
That study assumed that the hydrophobic tail of SDS was submerged within PDMS 217 
membrane, thus, resulting in the charged head group exposed to the donor solution. 218 
Therefore, it was proposed that the SDS impregnated membrane surface create a negatively 219 
charged environment which would, in turn, repel the neutral species of compound. This study 220 
found 20 mM SDS to produce a greater hindrance in permeation than all others (0, 4 and 8 221 
mM SDS) which, was suggested, was because of the coexistence of free monomer, monomer-222 
membrane surface interactions and micellisation. It is noticeable that the above-mentioned 223 
mechanisms offer a comprehensive explanation of SDS effect on the overall reduction in 224 
compound permeation. However, the fact that SDS produces a dissimilar effect for different 225 
compounds, cannot be addressed by applying these mechanisms.  226 
If only the unionised form of compound can permeate through PDMS membrane, the 227 
extent of permeation depends on the availability of compounds in unionised form in the 228 
donor compartment of the diffusion cell. In solution, an equilibrium exists between unionised 229 
and ionised forms while maintaining a specific ratio between the two forms depending on the 230 
pH of the solution. For example, in a buffer solution of pH 7.4, ibuprofen (pKa = 4.9[23]) 231 
would have 0.32 % of total as the neutral (unionised) and 91.68 % as the anionic (ionised) 232 
species whereas lidocaine (pKa = 7.8[24]) would have 24.02 % as the neutral and 75.98 % as 233 
the cationic species. This ratio gives the actual percentage of species in the donor solution, 234 
provided that they do not interact with other components such as surfactant. However, this 235 
might not be the case for lidocaine. As lidocaine produces cations in the solution, a portion of 236 
these ions might weakly bond the anionic head groups of SDS. In other words, a portion of 237 
cationic lidocaine molecules, from the bulk solution, will migrate to the SDS-submerged 238 
membrane surface. Therefore, to maintain the equilibrium ratio between two species (ionised 239 
and unionised) in the bulk solution a certain number of unionised species would be converted 240 
to the ionised form which, in turn, decreases the number of neutral (unionised) lidocaine 241 
molecules available to diffuse through the membrane. In the case of a micellar surfactant 242 
solution, an additional interaction can happen where the cationic lidocaine species interacts 243 
with SDS head groups in the micelles thus further decreasing the number of neutral lidocaine 244 
molecules that would pass through the membrane. In both cases, the permeation of lidocaine 245 
would be further reduced. These scenarios might not be observed for benzocaine, 246 
benzotriazole and ibuprofen, as upon ionisation they produce anions which would be repelled 247 
by the SDS head group, and stay in the bulk solution i.e. the equilibrium ratio of ionised and 248 
unionised forms would not be affected.  249 
A second type of surfactant was investigated in this study, namely a cationic 250 
surfactant, cetyltrimethylammonium bromide (CTAB). Fig. 2 shows the permeability profiles 251 
of the compounds in the presence of CTAB. Fig. 2, along with the calculated p-values (< 252 
0.05) clearly indicate that the compound fluxes were significantly influenced by the cationic 253 
surfactant being present in the donor solution.    254 
 255 
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 266 
Fig. 2. Effect of the presence of CTAB on compound permeation across PDMS membrane. 267 
Such an effect of CTAB was hypothesised in a previous study where it was assumed 268 
that CTAB would reduce the transport of paraben derivatives (the model compounds 269 
considered in the study) across PDMS membrane[17]. The hypothesis stated that CTAB 270 
would create a positively charged membrane surface i.e. the hydrophobic tail of CTAB would 271 
be submerged within PDMS membrane thus exposing the cationic head group to the donor 272 
solution, and consequently, this would reduce the likelihood of the permeation of neutral 273 
paraben molecules through the membrane. The same mechanism could be observed in this 274 
study. In other words, the positively charged CTAB-submerged membrane surface could 275 
repel the compound molecules away from the membrane resulting in an overall reduction in 276 
permeation. As mentioned earlier (in the case of SDS), though this mechanism may explain 277 
the reduction of compound permeation in general, it cannot clarify the inter-difference 278 
amongst the compounds in terms of percentage reduced. It can be seen from Fig. 2 that the 279 
percentage of the amount reduced by CTAB is different for each compound.  280 
Although both SDS and CTAB create a barrier effect in compound permeability, the 281 
overall trend they follow is different. From Fig. 1 and 2, if the percentages of overall 282 
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reduction are placed in an order, then for CTAB the order appears as ibuprofen > benzocaine 283 
> lidocaine > benzotriazole whereas, for SDS it becomes lidocaine > benzocaine > 284 
benzotriazole > ibuprofen. In general, the reduction effect of both these surfactants on 285 
compound permeation is different for each drug. Previously, it was mentioned that the 286 
difference produced by SDS was because of the interaction between its anionic head groups 287 
and ionised compound species in the donor solution. In the case of CTAB, the difference in 288 
compound reduction can be the result of the interaction between its cationic head groups and 289 
ionised species of the compounds. If the hydrophobic regions of CTAB are submerged in 290 
PDMS membrane this will expose the cationic head groups to the donor solution, making a 291 
positively charged membrane surface. A portion of anionic species, which are formed upon 292 
ionisation of acid compounds, may migrate to the positively charged membrane surface, and 293 
weakly bond the cationic head groups of CTAB. Consequently, to maintain the equilibrium 294 
ratio between ionised and unionised forms of acid compounds in the bulk solution, a number 295 
of unionised species are converted to the ionised (anionic) species, thus, decreasing the total 296 
available number of neutral molecules to be transported across the membrane. In the case of a 297 
micellar solution, the number of neutral molecules can be further decreased because of the 298 
interaction between the anionic form of the compound and the cationic head group of CTAB. 299 
In both scenarios, the compound would experience a reduction in transport through PDMS 300 
membrane. However, the aforementioned circumstances may not be observed for lidocaine as 301 
it forms a cation upon ionisation which is repelled by the cationic CTAB head. Unexpectedly, 302 
even though benzotriazole forms an anion upon ionisation, it was not affected by the 303 
scenarios mentioned above. One possible explanation for this anomaly is the comparatively 304 
high pKa of benzotriazole, indicating it is a very weak acid, compared with benzocaine and 305 
ibuprofen. Although this difference did not appear to be an influential factor when SDS was 306 
present, it may be significant enough to result in benzotriazole behaving in a similar way to 307 
lidocaine in the presence of CTAB. Alternatively, this anomaly may be the result of a 308 
complex chemical interaction which is currently unclear and the focus of current study. 309 
The third type of surfactant, investigated in this study, was a zwitterionic surfactant, 310 
namely CHAPS. The effect of CHAPS on compound permeation is shown in Fig. 3.                           311 
Fig. 3. Effect of the presence of CHAPS on compound permeation across PDMS membrane. 312 
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Figure 3 indicates that the overall permeation of compounds, except for ibuprofen, 313 
was not significantly affected by CHAPS. Additionally, the permeation of ibuprofen was 314 
reduced only in the presence of CHAPS being present at, and above its CMC which is 315 
between 4 and 6 mM[25]. At 2 mM, i.e. below the CMC, CHAPS did not affect ibuprofen 316 
permeation. This may be the result of an interaction between the ibuprofen molecules and 317 
CHAPS micelles as upon reaching the CMC, the surfactant forms micelles. The formation of 318 
surfactant micelles creates a hydrophobic core which contains the hydrophobic regions of 319 
surfactant and it is known that the hydrophobic core of micelles can strongly interact with 320 
hydrophobic molecules and entrap them inside the core [26]. A similar mechanism can be 321 
observed in this study where ibuprofen, with a log P value of 3.6[11], strongly interacted with 322 
the hydrophobic core of CHAPS micelles and became trapped inside them thus reducing the 323 
number of ibuprofen molecules available to cross through PDMS membrane. Consequently, 324 
there would be a reduction in ibuprofen permeation. As the other three compounds are 325 
relatively less hydrophobic, they might not as strongly interact with CHAPS micelles and 326 
hence, their fluxes would not be as significantly affected. 327 
This study also investigated the effect of a non-ionic surfactant, namely Brij 35, on 328 
drug transport across PDMS membrane. The results (Fig. 4) indicate that the presence of this 329 
non-ionic surfactant significantly retarded the overall transport of all compounds except for 330 
lidocaine. It can also be seen that the permeation of lidocaine and benzotriazole remain 331 
unaffected in the case of 4 mM Brij 35.  332 
Fig. 4. Effect of the presence of Brij 35 on compound permeation across PDMS membrane. 333 
 334 
In general, an increase in the concentration of Brij 35 resulted in a decrease in the flux 335 
of the compounds. Interestingly, this finding appears to be different than that observed in a 336 
recent study[17]. In that study Brij 35 was reported not to have a significant effect on 337 
compound permeation through PDMS membrane. The study considered paraben derivatives, 338 
namely, methylparaben and ethylparaben as model compounds. However, to confirm if this 339 
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phenomenon is a result of Brij 35 in particular (or a more broadly observed trend of non-ionic 340 
surfactant) a further study was carried out focusing on the permeation of three model 341 
compounds (benzocaine, ibuprofen and lidocaine) in the presence of another non-ionic 342 
surfactant, namely Tween 80 (Figure 5). 343 
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Fig. 5. Effect of the presence of Tween 80 on compound permeation across PDMS 357 
membrane. 358 
 Fig. 5 clearly shows that the presence of this non-ionic surfactant retards the 359 
permeation of the compounds in a similar trend to that observed for Brij 35. Therefore, it can 360 
be inferred that in the presence of this (and other) non-ionic surfactants does affect compound 361 
permeation. 362 
In summary, the current study demonstrates that all five surfactants investigated here 363 
had a significant effect on compound permeation. Comparing different concentrations of 364 
various surfactants, it is obvious from Table 1 that the solution containing 20 mM surfactant 365 
leads to the lowest flux of compound across PDMS membrane. However, while the 366 
surfactants show the greatest reduction effect at 20 mM, clear differences can be found in 367 
their effect at this concentration. It also appears that among the four surfactants tested, CTAB 368 
facilitates the lowest flux in the case of all compounds, except for lidocaine – the lowest flux 369 
of lidocaine was obtained in the presence of SDS and that the same trend was observed for 370 
the surfactants being present in the donor solution at a concentration of 4 mM.        371 
To confirm the surfactant-membrane interaction observed was an event that only 372 
occurred in situ, i.e. was not the result of a permanent alteration to the membrane surface, 373 
analysis was undertaken to characterise the membrane using DSC and FT-IR. Firstly, DSC 374 
thermograms of untreated membrane, along with surfactant pre-treated membrane, are shown 375 
in Figure 6. 376 
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Fig. 6. DSC thermograms for PDMS membrane with the addition of surfactants. 378 
 Previous research has observed a significant shift in the silicone membrane phase 379 
transition when the membrane has been pre-treated with certain solvents, indicating there has 380 
been a permanent interaction between those particular solvents and membrane[27]. In this 381 
work no such shift in phase transition temperature, i.e. melting transition temperature of the 382 
crystalline phase, was observed with all transitions at -40 °C thus confirming the interaction 383 
between surfactant and membrane in all cases is temporary and limited to occurring only 384 
when an aqueous solution of surfactant is in direct contact with PDMS. To further confirm 385 
this hypothesis, FT-IR analysis was undertaken for PDMS membrane and all surfactants, as 386 
summarised in Figure 7. 387 
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Fig. 7. FT-IR spectra for PDMS membrane with the addition of surfactants. 389 
 Once again, it is apparent from Figure 7 that all of the spectra are very similar 390 
confirming that there had been no change in chemical structure as a result of pre-treating the 391 
membrane surface with each surfactant. Furthermore, as a study to consider the effects of a 392 
range of surfactants on permeation through PDMS, this work has shown that it is uniquely 393 
possible to observe the effects of surfactants on the membrane in situ which were not 394 
observable using standard analytical techniques, such as DSC or FT-IR. 395 
Conclusion 396 
In conclusion, there is a clear surfactant effect on compound permeation across 397 
silicone membrane. The surfactants examined in this study appear to reduce the transport of 398 
four model compounds through the membrane. Overall, there was an inverse relationship 399 
between surfactant concentration and the amount of compound permeated. It was also 400 
observable that the effect of surfactant on compound permeation was different for different 401 
surfactant types, and also for different compounds. This variance was thought to result from a 402 
variation in the interaction of the charged and neutral compound species with the surfactant 403 
head group, and/or the surface and core of the surfactant micelle. Comparing all four 404 
surfactants, CTAB appeared to facilitate the lowest flux of compound through silicone 405 
membrane.   406 
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